Camptothecin and 9-Nitrocamptothecin (9NC) as Anti-cancer, Anti-HIV and Cell-differentiation Agents. Development of Resistance, Enhancement of 9NC-induced Activities and Combination Treatments in Cell and Animal Models

Anticancer Research

Volumn 23, Issue 5 A, 2003, Pages 3623-3638

  Pantazis, Panayotis ^a,b   Han, Zhiyong ^a   Balan, Kannan ^a   Wang, Yongbao ^a   Wyche, James H ^a  

^a Department of Biology   (United States)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

9 nitrocamptothecin; Anti cancer agents; Anti HIV; Campthothecin; Cell differentiation; Resistance; Review

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE; DNA TOPOISOMERASE; ETOPOSIDE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RUBITECAN; VINCRISTINE;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL TYPE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TOLERANCE; ENCAPSULATION; GENE MUTATION; HUMAN; HYPERTHERMIA; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION; XENOGRAFT;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; HIV-1; HUMANS; VIRUS REPLICATION;

EID: 0344442301     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (199)

1. Wall ME and Wani MC: Chemistry and antitumor activities of camptothecins. In: DNA Topoisomerases in Cancer (M Potmesil and KW Kohn, eds), New York, Oxford University Press, 1991, pp 93-102.
2. Wall ME and Wani MC: Camptothecin. Discovery to clinic. Ann NY Acad Sci 803: 1-12, 1996.
3. Pourquier P and Pommier Y: Topoisomerase I-mediated DNA damage. Adv Cancer Res 80: 190-216, 2001.
4. Li T-K and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41: 53-77, 2001.
5. Muggia FM: Twenty years later: review of clinical trials with camptothecin sodium (NSC 100880). In: Camptothecins: New Anticancer Agents (M Potmesil and H Pinedo H, eds), pp. 43-53, Boca Raton, CRC Press, 1995.
6. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER and Giovanella BC: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncology Res 5: 273-281, 1993.
7. Pantazis P, Kozielski A, Rodriguez R, Petry E, Wani M, Wall M and Giovanella B: Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4: 5-10, 1994.
8. Pantazis P, Han Z, Chatterjee D and Wyche J: Drugs of the Future 24: 1311-1323, 1999.
9. Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, Wani MC and Wall ME: Camptothecin analogues with enhanced antitumor activity. Cancer Chemother Pharmacol 146: 263-271, 2000.
10. Garcia-Carbonero R and Supko JG: Current prospectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641-661, 2002.
11. Ulukan H and Swaan PW: Camptothecins: a review of their chemotherapeutic potential. Drugs 62: 2039-2057, 2002.
12. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G and Verweij J: Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76: 952-962, 1997.
13. O'Leary J and Muggia FM: Camptothecins: a review of their development and schedules of administration. Eur J Cancer 34: 1500-1508, 1998.
14. Pantazis P, Early JA, Mendoza JT, De Jesus AR and Giovanella BC: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54: 771-776, 1994.
15. Wani MC, Nicholas AW and Wall ME: Plant antitumor agents 23. Synthesis and antileukemia activity of camptothecin analogs. J Med Chem 29: 23-58, 1986.
16. Pantazis P, Harris N, Mendoza J and Giovanella B: Conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human blood cells in vitro. Eur J Haematol 53: 246-248, 1994.
17. Hinz HR, Harris N, Natelson EA and Giovanella BC: Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-(S)-camptothecin to 9-amino-(S)-camptothecin in humans, dogs, and mice. Cancer Res 54: 3096-3100, 1994.
18. Hsiang Y-H, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
19. Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3: 430-440, 2002.
20. Topcu Z: DNA topoisomerases as targets for anticancer drugs. J Clin Pharmacol Ther 26: 405-416, 2001.
21. Champoux JJ: DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413, 2001.
22. Liu LF, Desai SD, Li TK, Mao Y, Sun M and Sim SP: Mechanism of action of camptothecin. Ann NY Acad Sci 922: 1-10, 2000.
23. Leteurtre F, Fesen M, Kohlhagen G, Kohn KW and Pommier Y: Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry 3: 8955-8962, 1994.
24. Yoshida A, Ueda T, Wano Y and Nakamura T: DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 84: 566-573, 1993.
25. Jaxel C, Kohn KW, Wani MC, Wall ME and Pommier Y: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465-1469, 1989.
26. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella BC and Kufe D: Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J Biol Chem 269: 2433-2439, 1994.
27. Saleem A, Ibrahim N, Patel M, Li X-G, Mendoza J, Pantazis P and Rubin EH: Mechanism of cellular resistance to sequential topoisomerase poisoning. Cancer Res 57: 5100-5106, 1997.
28. Nuñez G, Benedict MA, Hu Y and Inohara K: Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-3245, 1998.
29. Strasser A, O'Connor L and Dixit VM: Apoptosis signaling. Annu Rev Biochem 69: 217-245, 2001.
30. Bratton SB and Cohen GM: Apoptotic death sensor: an organelle's alter ego? Trends Pharnacol Sci 22: 306-315, 2001.
31. Inoue S, Salah-Eldin AE and Omoteyama K: Apoptosis and anticancer drug resistance. Hum Cell 14: 211-221, 2001.
32. Zimmermann KC, Bonzon C and Green DR: The machinery of programmed cell death. Pharmacol Ther 92: 57-70, 2001.
33. Mow BM, Blajeski AL, Chandra J and Kaufmann SH: Apoptosis and the response to anticancer therapy. Curr Opin Oncol 13: 453-462, 2001.
34. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K and Wesselborg S: Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 59: 2083-2090, 1999.
35. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM and Giaccone G: Drug-induced apoptosis in lung cancer is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 6: 203-212, 2000.
36. Goncalves A, Braguer D, Carles G, Andre N, Prevot C and Briand C: Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol 60: 1579-1584, 2000.
37. Jones DT, Ganeshaguru K, Virchis AE, Folarin NI, Lowdell MW, Mehta AB, Prentice HG, Hoffbrand AV and Wickremasinghe RG: Caspase-8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 98: 2800-2807, 2001.
38. Adams JM and Cory S: Life-or-death decision by the Bcl-2 protein family. Trends Biochem Sci 26: 61-66, 2000.
39. Baliga BC and Kumar S: Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20: 63-74, 2002.
40. Huang Z: Bcl-2 family proteins as targets for anticancer drugs design. Oncogene 19: 6627-6631, 2000.
41. Harris MH and Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7: 1182-1191, 2000.
42. Loeffler M and Kroemer G: The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 256: 19-26, 2000.
43. Li H, Zhu H, Hu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
44. Yin XM: Signal transduction mediated by Bid, a pro-death Bcl-2 family protein, connects the death receptor and mitochondria apoptosis pathways. Cell Res 10: 161-167, 2000.
45. Esposti MD: The roles of Bid. Apoptosis 7: 433-440, 2002.
46. Costa-Pereira AP and Cotter TG: Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 80: 371-378, 1999.
47. Shimizu T and Pommier Y: Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 11: 1238-1244, 1997.
48. Adjei PN, Kaufmann SH, Leung W-Y, Mao F and Gores GJ: Selective induction of apoptosis in Hep3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. J Clin Invest 98: 2588-2596, 1996.
49. Ferraro C, Quemeneur L, Fournel S, Prigent AF, Revillard JP and Bonnefoy-Berard N: The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes. Cell Death Differ 7: 197-206, 2000.
50. Stefanis L, Parks DS, Friedman WJ and Greene LA: Caspase-dependent and -independent death of camptothecin-treated embryonic cortical neurons. J Neurosci 19: 6235-6247, 1999.
51. Keramaris E, Stefanis L, MacLaurin J, Harada N, Takaku K, Ishikawa T, Taketo MM, Robertson GS, Nicholson DW, Slack RS and Parks: Involvement of caspase 3 in apoptotic death of cortical neurons evoked by DNA damage. Mol Cell Neurosci 15: 368-379, 2000.
52. Sané A-T and Bertrand R: Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. Cancer Res 59: 3565-3569, 1999.
53. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW and Shi YF: Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 88: 333-347, 2000.
54. Petak I and Houghton JA: Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 7: 95-106, 2001.
55. Wajant H: The Fas signaling pathway: more than a paradigm. Science 296: 1635-1636, 2002.
56. Micheau O, Solary E, Hammann A, Martin F and Dimanche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783-789, 1997.
57. Shao RC, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E and Pommier Y: Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 20: 1852-1859, 2001.
58. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirschhoff S, Krammer PH, Peter ME, Wyche JH and Pantazis P: Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res 61: 7148-7154, 2001.
59. Nieves-Neira W and Pommier Y: Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 82: 396-404, 1999.
60. Leung LK and Wang TT: Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 55: 73-83, 1999.
61. Li G, Bush JA and Ho VC: P53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114: 514-519, 2000.
62. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ and Kohn KW: Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853-1861, 1993.
63. Bedner E, Li X, Kunicki J and Darzynkiewicz Z: Translocation of Bax to mitochondria during apoptosis measured by laser scanning cytometry. Cytometry 41: 83-88, 2000.
64. In: The Anticancer Drugs (WB Pratt, RW Ruddon, WD Ensminger and J Maybaum, eds), Chapter: Potential targets for new anticancer drugs. New York, Oxford University Press, 1994, pp 306-336.
65. Warrell RP: Differentiation agents. In: The Chemotherapy Source Book (MC Perry, ed). Philadelphia, Lippincott Williams & Wilkins, 2001 pp 304-312.
66. Scott RE: Differentiation, differentiation/gene therapy and cancer. Pharmacol Ther 73: 51-65, 1997.
67. Nakaya K, Chou S, Kaneko M and Nakamura Y: Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jpn Cancer Res 82: 184-191, 1991.
68. Chou S, Kaneko M, Nakayha K and Nakamura Y: Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem Biophys Res Commun 1656: 160-167, 1990.
69. McSheehy PMJ, Gervasoni M, Lampasona V, Erba E and D'Incalci M: Studies of the differentiation properties of camptothecin in the human leukemic cells K562. Eur J Cancer 27: 1406-1411, 1991.
70. Aller P, Rius C, Mata F, Zorilla A, Cabanas C, Bellon T and Bernabeu C: Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promyelocytic leukemia cells. Cancer Res 52: 1245-1251, 1992.
71. Kharbanda S, Rubin E, Gunji H, Hinz H, Giovanella B, Pantazis P and Kufe D: Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res 51: 6636-6642, 1991.
72. Mitchell PI and Tjian R: Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 245: 371-378, 1989.
73. Zhang H, Wang JC and Liu LF: Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 85: 1060-1064, 1988.
74. Merino A, Madden KR, Lane WS, Champoux JJ and Reinberg D: DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365: 227-232, 1993.
75. Schönfeld S, Schulz S and Nyce JW: Effects of inhibitors of topoisomerase I and II on DNA methylation and DNA synthesis in human colonic adenocarcinoma cells in vitro. Int J Oncol 1: 807-815, 1992.
76. Naveh-Many T and Cedar H: Active gene sequences are undermethylated. Proc Natl Acad Sci USA 78: 4246-4250, 1981.
77. Riggs AD and Jones PA: 5-Methylcytosine, gene regulation and cancer. Adv Cancer Res 40: 1-30, 1983.
78. Gieseler F, Boege F, Clark M and Mayer P: Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoietic cell differentiation. Toxicol Lett 67: 331-340, 1993.
79. Pantazis P, Hinz H, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS and Giovanella BC: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980-3987, 1992.
80. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC: Regression of human breast carcinomas in immunodeficient mice treated with 9-nitrocamptothecin: differential response of non-tumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53: 1577-1582, 1993.
81. Pantazis P, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53: 863-871, 1993.
82. Khaoustov VI, Ozer A, Smith JR, Noda A, Mearns M, Krishnan B, Stagle BL and Yoffe B: Induction of senescence-derived inhibitor of DNA synthesis gene, SDII, in hepatoblastoma (HepG2) cells arrested in the G2-phase of the cell cycle by 9-nitrocamptothecin. Lab Invest 73: 118-127, 1995.
83. Pantazis P, Chatterjee D, Han Z and Wyche J: Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro. Neoplasia 1: 231-240, 1999.
84. te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP: DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876-1883, 2002.
85. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan K, Pantazis P and Wyche JH: Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J Biol Chem 277: 17154-17160, 2002.
86. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I and Pereira-Smith OM: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Nat Acad Sci USA 92: 9363-9367, 1995.
87. Wei W, Hemmer RM and Sedivy JM: Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol 21: 6748-6757, 2001.
88. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551, 1994.
89. Chen Q, Fischer A, Reagan JD, Yan LJ and Ames BN: Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 92: 4337-4341, 1995.
90. Robles SJ and Adami GR: Agents that cause DNA double strand breaks lead to p16NK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 16: 1113-1123, 1998.
91. Haseltine WA: Molecular biology of the human immunodeficiency virus type 1. FASEB J 5: 2349-2360, 1991.
92. Steffy K and Wong-Staal F: Genetic regulation of human immunodeficiency virus. Microbiol Rev 55: 193-205, 1991.
93. Huang L-M, Joshi A, Willey R, Orenstein J and Jean K-T: Human immunodeficiency viruses regulated by alterfiative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J 12: 2886-2896, 1994.
94. Priel E, Showalter SD, Roberts M, Oroszlan S, Segar S, Aboud M and Blair DG: Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J 12: 4167-4172, 1990.
95. Takahasi H, Matsuda M, Kojima A, Sta T, Andoh T, Kurata T, Nagashima K and Hall WW: Human immunodeficiency virus type I reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I. Proc Natl Acad Sci USA 92: 5694-5698, 1995.
96. Priel E, Showalter SD and Blair DG: Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res. Human Retrov 7: 65-72, 1991.
97. Pommier Y, Podderin B, Gupta M and Jenkins J: DNA topoisomerases I and II cleavage sites in DNA promoter region. Biochem Biophys Res Commun 200: 1601-1609, 1991.
98. Moulton S, Pantazis P, Epstein JS and Sadaie MR: 9-Nitrocamptothecin inhibits tumor necrosis factor-mediated activation of human immunodeficiency virus type I and enhances apoptosis in a latently infected T cell clone. AIDS Res Human Retrov 14: 39-49, 1998.
99. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH and Fauci AS: Tumor necrosis factor-α induces expression of human immunodeficiency virus in a chronically-infected T-cell clone. Proc Natl Acad Sci USA 86: 2365-2368, 1989.
100. Wahl SM, Orenstein JM and Smith PD: In: Immunology of HIV Infection (S Gupta, ed), New York, Plenum Press, 1996, pp 303-336.
101. Sadaie MR, Doniger J, Hung C-L and Pantazis P: 9-Nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells. AIDS Res Human Retrov 15: 239-245, 1999.
102. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, Delpolyi PD, Harris N and Stehlin JS: Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY Acad Sci 803: 224-230, 1996.
103. Hung C-L, Doniger J, Palini A, Snyder SW, Radonovich MF, Brady JN, Pantazis P and Sadaie MR: 9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. J Med Virol 64: 238-244, 2001.
104. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
105. Carr AM, Green MH and Lehmann AR: Checkpoint policing by p53. Nature 359: 486-487, 1992.
106. Marx J: New link found between p53 and DNA repair. Science 266: 1321-1322, 1994.
107. Sharpless NE and DePinho RA: p53: good cop/bad cop. Cell 110: 9-12, 2002.
108. Israels ED and Israels LG: The cell cycle. Stem Cells 19: 88-91, 2001.
109. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181, 2001.
110. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
111. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachomial A and Woloschak GE: Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 77: 1007-1021, 2001.
112. Ligget WH and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197-1206, 1998.
113. Bringold F and Serrano M: Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 35: 317-329, 2000.
114. Sgambato A, Cittadini A, Faraglia B and Weinstein IB: Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183: 18-27, 2000.
115. Philipp-Staheli J, Payne SR and Kemp CJ: p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264: 248-168, 2001.
116. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
117. 1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8: 2540-2551, 1994.
118. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI: P53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
119. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
120. Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18: 546-557, 1998.
121. waf1 can block cells at two points in the cell cycle, but it does not interfere with progressive DNA-replication or stress-activated kinases. Oncogene 16: 431-441, 1998.
122. Wang J and Walsh K: Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273: 359-361, 1996.
123. Puri PL, Medaglia S, Cimino L, Maselli C, Germani A, DeMarzio E, Levrero M and Balsamo C: Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. J Cell Biochem 66: 27-36, 1997.
124. Cip/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev 10: 3065-3075, 1996.
125. (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp Cell Res 227: 171-181, 1996.
126. Marks P, Richon VM and Rifkind RA: Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: molecular and clinical studies employing hybrid polar compounds. Int J Hematol 63: 1-17, 1996.
127. (WAF1/C1P1) during differentiation of HL-60 cells by tumor necrosis factor alpha. Int J Hematol 65: 41-48, 1996.
128. Liu M, Lee MH, Cohen M, Bommakanti M and Freedman LP: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the promyelocytic cell line U937. Genes Dev 10: 142-153, 1996.
129. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activate p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406, 1994.
130. Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albimo AP and Scheinberg DA: Modulation of p53, WAF1/p21 and Bcl-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leukemia 21: 439-447, 1997.
131. Kikuchi J, Furukawa Y, Iwase S, Terui Y, Nakamura M, Kitagawa S, Kitagawa M, Komatsu N and Miura Y: Polyploidization and functional mutation are two distinct processes during megakaryocytic differentiation: involvement of cyclin-dependent kinase inhibitor p21 in polyploidization. Blood 89: 3980-3990, 1997.
132. Yang Z-Y, Perkins ND, Ohno T, Nabel EG and Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1: 1052-1056, 1995.
133. Landau M, Weizman A, Zoref-Shani E, Beery E, Wasserman L, Landau O, Gavish M, Brenner S and Nordenberg J: Antiprolifetative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochem Pharmacol 56: 1029-1034, 1998.
134. Rauth S, Kichina J and Green A: Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. Br J Cancer 75: 1559-1566, 1997.
135. Glaise D, Ilyin GP, Loyer P, Cariou S, Bilodeau M, Lucas J, Puisieux A, Ozturk M and Guguen-Guillouzo C: Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. Cell Growth Differ 9: 165-176, 1998.
136. INK4a-mediated growth suppression. Mol Cell Biol 18: 5284-5290, 1998.
137. CDKN2A in cell cycle delay after low dose of UV irradiation. Mut Res 422: 43-53, 1998.
138. Bartkova M, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J: The p16-cyclin D/cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56: 5475-5483, 1996.
139. INK4/CDKN2 gene in cutaneous malignant melanoma correlated with tumor cell proliferation and invasive stage. Int J Cancer 74: 255-259, 1997.
140. Grover R, Chana JS, Wilson GD, Richman PI and Sanders R: An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res 8: 267-272, 1998.
141. Stein GS, Drullinger LF, Soulard A and Dulic V: Differential roles for cyclin-dependent inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19: 2109-2117, 1999.
142. Castellano M, Gabrielli BG, Hussussian CJ, Dracopoli NC and Hayward NK: Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol 109: 61-68, 1997.
143. Solary E, Bertrand R and Pommier Y: Apoptosis by DNA topoisomerase I and II in human leukemic HL-60 cells. Leuk Lymphoma 15: 21-32, 1994.
144. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM and Pommier Y: Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res 3: 1653-1660, 1997.
145. Zhang ZW, Patchett SE and Farthing MJ: Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity. Anticancer Drugs 11: 757-764, 2000.
146. Li G, Bush JA and Ho VC: P53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 114: 514-519, 2000.
147. Ljungman M, O'Hagan HM and Paulsen MT: Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20: 5964-5971, 2001.
148. Morris EG, Keramaris E, Rideout HJ, Slack RS, Dyson NJ, Stefanis L and Parks DS: Cyclin-dependent kinases and p53 pathways are activated independently and mediate bax activation in neurons after DNA damage. J Neurosci 21: 5017-5026, 2001.
149. Waldman T, Lengauer C, Kinzler KW and Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716, 1996.
150. Bunz F, Hwang P M, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269, 1999.
151. Brown J M and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999.
152. Pantazis P, Mendoza JT, DeJesus A, Rubin E, Kufe D and Giovanella BC: Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. Eur J Haematol 43: 135-144, 1994.
153. Pantazis P, Mendoza JT, Kozielski AJ, Natelson EA and Giovanella BC: 9-Nitrocamptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur J Haematol 50: 81-89, 1993.
154. 2 arrest: altered regulation of p34(cdc2)/cyclin B. Cancer Res 52: 1823-1829, 1992.
155. Shimizu T, O'Connor PM, Kohn KW and Pommier Y: Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55: 228-231, 1995.
156. Chatterjee D, Wyche JH and Pantazis P: Up-regulation of cyclin B and cdc2 expression during 9-nitrocamptothecin-induced regression of DU145 prostate tumor. Anticancer Res 20: 4477-4482, 2002.
157. Chang JY, Liu JF, Juang SH, Liu TW and Chen LT: Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res 62: 3716-3721, 2002.
158. Pantazis P: Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res 1: 1235-1244, 1995.
159. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioiffre C, Chatterjee D, Pantazis P and Pommier Y: Characterization of a novel topoisomerase I mutation from a camptothecin-resistant prostate cancer cell line. Cancer Res 61: 1964-1969, 2001.
160. Piret B and Pierre J: Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res 24: 4242-4248, 1996.
161. Habraken Y, Piret B and Pierre J: S phase dependence and involvement of NF-kappaB activating kinase to NF-kappaB activation by camptothecin. Biochem Pharmacol 62: 603-616, 2001.
162. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA and Miyamoto S: NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 275: 9501-9509, 2000.
163. Singh S, Raju U, Mendoza J, Pantazis P and Aggarwal BB: Acquisition of cellular resistance to 9-nitrocamptothecin correlates with suppression of transcription factor NF-kB activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells. Anti-Cancer Drugs 9: 703-714, 1998.
164. Kataoka T, Budd RC, Holler N, Thome M, Matinon F, Irmler M, Burns K, Hahne M, Kennedy N, Kovacsvics M and Tschopp J: The caspase-8 inhibitor FLIP promotes activation of NF-kB and Erk signaling pathways. Curr Biol 10: 640-648, 2000.
165. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, Grell M, Smith C and Scheuurich P: Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level or upstream of Fas-associated death domain protein (FADD). J Biol Chem 275: 24357-24366, 2000.
166. Chatterjee D, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Sedivy JM and Yeung KC: RKIP sensitizes cancer cells to apoptosis. Submitted.
167. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Kastanakis KD, Rose DW, Mischak H, Sedivy LM and Kolch W: Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature 401: 173-177, 1999.
168. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W and Sedivy JM: Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappa B activation. Mol Cell Biol 21: 7207-7217, 2001.
169. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y and Weinstein JN: Apoptotic susceptibility of cancer cells selected
170. Han Z, Cao Z, Chatterjee D, Wyche J and Pantazis P: Propionate and butyrate esters of camptothecin and 9-nitrocamptothecin as antileukemia prodrugs in vitro. Eur J Haematol 62: 246-255, 1999.
171. Cao Z, Harris N, Kozielski A, Vardeman D, Stehlin JS and Giovanella B: Alkyl esters of camptothecin and 9-nitro camptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 41: 31-37, 1998.
172. Knight V, Koshkina NV, Waldrep JF, Giovanella BC and Gilbert BE: Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44: 177-186, 1999.
173. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE and Knight V: 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6: 2876-2880, 2000.
174. Pantazis P, Vardeman D, Mendoza J, Early J, Kozielski A, DeJesus A and Giovanella B: Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leuk Res 19: 43-55, 1995.
175. Pantazis P, DeJesus A, Early J, Rodriguez R, Chatterjee D, Han Z, Wyche J and Giovanella B: Development of human leukemia U-937 cell sublines resistant to doxorubicin: induction of differentiation and altered sensitivities to topoisomerase-directed drugs. Anticancer Res 15: 1873-1881, 1995.
176. Chatterjee D, Wyche J and Pantazis P: Induction of apoptosis in malignant and camptothecin-resistant human cells. Ann NY Acad Sci 803: 143-156, 1996.
177. Beck WT: Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerase in drug action and resistance. J Natl Cancer Inst 81: 1683-1685, 1989.
178. Tan KB, Mattern MR, Eng W-K, McCabe FL and Johnson RK: Nonreproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735, 1989.
179. Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF and Tsuruo T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965, 1990.
180. Chen AY, Choy H and Rothenberg ML: DNA topoisomerase I-targeted drugs as radiation sensitizers. Oncology 13: 39-46, 1999.
181. Mehta MP, Tome WA and Olivera GH: Radiotherapy for brain tumors. Curr Oncol Rep 2: 438-444, 2000.
182. Musk SRR and Steel GG: The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase I. Br J Cancer 62: 364-367, 1990.
183. Boothman DA, Wang M, Schea RA, Burrows NL, Strickfaden S and Owens JK: Port-treatment exposure to camptothecin unbalanced the lethal effects of x-rays on radioresistant malignant melanoma cell. Int J Radiat Oncol Biol Phys 24: 939-948, 1992.
184. Boscia RE, Korbut T, Holden SA, Ara G and Teicher BA: Interaction of topoisomerase I inhibitors with radiation in cis-diaminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 53: 118-123, 1993.
185. Falk SJ and Smith PJ: DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human calls. Int J Radiat Biol 61: 749-757, 1992.
186. Del Bino G, Bruno S, Yi PN and Daezynkiewicz Z: Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prol 25: 537-548, 1992.
187. Hennequin C, Giocanti N, Baloss J and Favaudon Y: Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54: 1720-1728, 1994.
188. Chen BM, Chen JY, Kao M, Lin JB, Yu MH and Roffler SR: Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol Oncol 79: 272-280, 2000.
189. Miyamoto S, Huang TT, Wuerzberger-Davis S, Bornmann WG, Pink JJ, Tagliarino C, Kinsella TJ and Boothman DA: Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann NY Acad Sci 922: 275-292, 2000.
190. Kim JS, Amorino GP, Pyo H, Cao Q and Choy H: Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol 62: 61-67, 2002.
191. Pantazis P, Early JA, Mendoza JT, DeJesus AR and Giovanella BC: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54: 771-776, 1994.
192. Steffer JR, Rimner A, Rieger J, Naumann U, Rodemann HPM and Weller M: Bcl-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol 56: 43-49, 2002.
193. Mao Y, Okada S, Chang LS and Muller MT: p53 dependence of topoisomerase I recruitment in vivo. Cancer Res 60: 4538-4543, 2000.
194. Hahn GM: Thermal enhancement of the actions of anticancer agents. In: Hyperthermia and Cancer (GM Hahn, ed), New York, Plenum Publishing Corp., 1992, pp 55-86.
195. Fisher GA and Hahn GM: Enhancement of cis-platinum (II)diaminedichloride cytotoxicity by hyperthermia. Natl Cancer Inst Monogr 61: 255-257, 1982.
196. Teicher BA, Holden SA, Khandakar V and Herman TS: Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diaminedichloro-platinum(II)/heat/radiation] in a murine tumor. J Cancer Res Clin Oncol 119: 645-651, 1993.
197. Valenzuela MH, Nunez MI, Villalobos M, Siles E, McMilan TJ, Pedraza V and Ruiz de Almondovar JM: A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation. Intl J Cancer 72: 307-312, 1997.
198. Pantazis P, Chatterjee D, Han Z and Wyche J: Modulation of 9-nitrocamptothecin-induced apoptosis by hyperthermia in human leukemia HL-60 cells. Anticancer Drugs 10: 317-322, 1999.
199. Gautam A, Waldrep JC, Densmore CL, Koshkina N, Melton S, Roberts L, Gilbert B and Knight V: Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 9: 353-357, 2000.